May 20, 2021

Altavant Sciences Reports Rodatristat Ethyl PK/PD Analysis at ATS Supporting Doses Selected for Phase 2b ELEVATE 2 Study

Altavant Sciences presented findings at the recent ATS meeting from a dose-response model, which simulated daily administration of rodatristat ethyl to identify optimal doses for the Phase 2b ELEVATE 2 study. Read More »

May 10, 2021

Altavant Sciences Provides Update on Clinical Plan for PAH Candidate, Rodatristat Ethyl, at Upcoming American Thoracic Society Annual Meeting

Altavant Sciences will be providing an update on the clinical development of rodatristat ethyl, the company's lead candidate for the treatment of pulmonary arterial hypertension (PAH), at the annual meeting of the American Thoracic Society. Read More »

May 6, 2021

Altavant Sciences Advances Rodatristat Ethyl into Phase 2b Clinical Trial for Pulmonary Arterial Hypertension

Altavant Sciences initiated its Phase 2b ELEVATE 2 Study of its lead product candidate, rodatristat ethyl, for the treatment of patients with pulmonary arterial hypertension. Read More »

April 26, 2021

Altavant Sciences Finds Nebulized ALTA-2530 Retains Potency and Reaches Target Lung Tissues, Supporting Continued Investigation for Treatment of BOS

Altavant Sciences presented results of in vitro and in vivo studies for nebulized ALTA-2530, a novel inhaled formulation of recombinant human IL-1Ra currently in nonclinical development for the treatment of BOS Read More »

February 18, 2021

Altavant Sciences Initiates Chemical Lung Injury Program in Collaboration with the BARDA and NIAID

Altavant Sciences has partnered with the US Department of Health and Human Services (HHS) BARDA and NIAID to execute an initial in vivo proof-of-concept pilot study of ALTA-2530, a novel inhaled formulation of a recombinant IL-1Ra for the treatment of acute and chronic lung injuries Read More »

August 5, 2020

Altavant Sciences Presentation at ATS 2020 Confirms Minimal Brain Exposure of Peripherally Acting Serotonin Modulator, Rodatristat Ethyl, in Clinical Development for PAH

Altavant Sciences presented results from in vivo nonclinical studies of rodatristat ethyl, which demonstrated enhanced distribution in lung tissue consistent with levels associated with disease modification in preclinical models Read More »

March 2, 2020

Altavant Sciences Appoints Respiratory Disease Medical Expert as Chief Medical Officer

Altavant Sciences appointed Howard M. Lazarus, M.D., to the newly created position of Chief Medical Officer. Dr. Lazarus brings more than 20 years of experience in drug development for pulmonary vascular and interstitial diseases and as a practicing pulmonologist. Read More »

January 8, 2020

Altavant Sciences Acquires Onspira Therapeutics, Adding a Potentially Life-Saving Treatment for Post-Lung Transplant Patients to the Altavant Pipeline

Altavant Sciences has entered into a definitive agreement to acquire Onspira Therapeutics, a private drug development company similarly focused on therapeutics for rare pulmonary diseases.  Read More »

October 22, 2019

Altavant Sciences Presents Data at CHEST 2019 Supporting Once-Daily Dosing of Rodatristat Ethyl for the Treatment of Pulmonary Arterial Hypertension

Altavant Sciences announced mechanistic preclinical pharmacodynamic and Phase 1 data supporting once-daily dosing of rodatristat ethyl for the treatment of PAH. These data were presented as a poster delivered as a short oral presentation at CHEST2019 Read More »

October 18, 2019

Altavant Sciences to Present Data Supporting Once-Daily Dosing of Rodatristat Ethyl at CHEST 2019

Altavant Sciences announced that its scientific team will be presenting preclinical safety, PK and biomarker PD data at the annual CHEST 2019 meeting being held October 19 - 23 in New Orleans, Louisiana. Read More »

October 1, 2019

Altavant Sciences Presents Data at ERS International Congress 2019 Demonstrating Strong Safety and Tolerability Profile of Rodatristat Ethyl

Altavant Sciences announced new clinical data from two Phase 1 trials of rodatristat ethyl, demonstrating favorable safety and tolerability in healthy volunteers, and mechanistic biomarker data consistent with efficacy in nonclinical models of PAH Read More »

September 24, 2019

Altavant Sciences to Present New Rodatristat Ethyl Clinical Biomarker and Safety Findings at the ERS International Congress 2019

Altavant Sciences announced that its scientific team will present clinical safety, PK and biomarker data from two Phase 1 clinical studies of rodatristat ethyl at the 29th ERS being held September 28 - October 2 in Madrid, Spain. Read More »

September 5, 2019

Sumitomo Dainippon Pharma and Roivant Sciences Enter into a Memorandum of Understanding to Create Broad Strategic Alliance to Deliver Promising New Medicines to Patients

Sumitomo Dainippon Pharma and Roivant Sciences announced the creation of a novel and broad Alliance to include the transfer to Sumitomo Dainippon Pharma of Roivant's ownership interests in 5 of their biopharmaceutical companies, with options to acquire up to 6 additional Vants, and access to Roivant's proprietary technology platforms, DrugOme and Digital Innovation Read More »

September 5, 2019

Altavant Sciences Presents Patient-Centric Approach to Drug Development at PHA’s Annual PHPN Symposium

Altavant Sciences today announced a poster presentation describing the company's unique, patient-centric drug development process at the Pulmonary Hypertension Association's Annual PHPN Symposium taking place September 5-7, 2019 in Washington, D.C. Read More »

August 5, 2019

Altavant Sciences Initiates Phase 2a Study of Rodatristat Ethyl in Pulmonary Arterial Hypertension

Altavant Sciences dosed the first patient in the ELEVATE 1 proof-of-concept Phase 2a study of rodatristat ethyl in patients with PAH. The study is designed to provide valuable safety, target engagement and biomarker information Read More »

May 9, 2019

Altavant Sciences to Provide Clinical Update at 2019 Respiratory Innovation Summit

Altavant Sciences today announced that it has been invited to present at the 2019 Respiratory Innovation Summit May 17 in Dallas, TX. Lyn Baranowski, will present an overview of the company and its lead tryptophan hydroxylase (TPH) inhibitor Read More »

January 31, 2019

Altavant Sciences to Present Data Supporting Planned Phase 2 Clinical Program for Rodatristat Ethyl in Patients with Pulmonary Arterial Hypertension at PVRI World Congress

Altavant Sciences will present its latest nonclinical and clinical data at the PVRI 13th Annual World Congress on Pulmonary Vascular Disease, taking place in Barcelona from January 30 to February 3, 2019. These results provide additional evidence that treatment with rodatristat ethyl facilitates vascular remodeling and ameliorates PAH in animal models.  Read More »

January 2, 2019

Altavant Sciences Appoints Lyn Baranowski Chief Operating Officer

Altavant Sciences announced the appointment of Lyn Baranowski as Chief Operating Officer. In this new position, she will be involved in the general management of the company, leading cross-functional teams to establish and execute on a business and financing strategy that will deliver on the company's short- and long-term business objectives. Read More »

Media

Roivant Pipeline Day

Altavant CEO Bill Symonds presents

Get in Contact

[email protected]

Media inquiries: Aline Sherwood

[email protected]